


Express Mail No.: EV 074978332 US  
Date of Deposit: July 18, 2002

Attorney Docket No.: 15966-557A (Cura-57A)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Jeffers, et al.  
SERIAL NUMBER : 09/992,840 EXAMINER : Not Yet Assigned  
FILING DATE : November 6, 2001 ART UNIT : Not Yet Assigned  
FOR : Treatment of Inflammatory Bowel Disease Using Growth Factors

BOX IDS

Commissioner for Patents  
Washington, D.C. 20231



30623

PATENT TRADEMARK OFFICE

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (1 page), in duplicate;
2. Modified Form 1449/PTO (3 pages), in duplicate;
3. Copies of Cited References B1 and C1-C46; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 15966-557A. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

*Ivor R. Elrifi* Reg No 44,848

Ivor R. Elrifi, Registration No. 39,529  
Attorneys for Applicants  
MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY and POPEO, P.C.  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

Dated: July 18, 2002

TRA 1686954v1



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT(S): Jeffers, et al.

SERIAL NUMBER: 09/992,840

FILING DATE: November 6, 2001

FOR: Treatment of Inflammatory Bowel Disease Using Growth Factors

EXAMINER: Not Yet Assigned

ART UNIT: Not Yet Assigned

**BOX IDS**

Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed Form PTO-1449 to evidence that the cited information has been fully considered by the PATENT AND TRADEMARK OFFICE during the examination of this application.

Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 Reference No. 15966-557A (Cura-57A).

Respectfully submitted,

*KE Elrifi, Reg No 44,848*

Ivor R. Elrifi, Registration No. 39,529

Attorney for the Applicants

c/o MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY and POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000

Fax: (617) 542-2241

Dated: July 18, 2002

Please type a plus sign (+) in this box



PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	09/992,840
	<b>Filing Date</b>	11/06/01
	<b>First Named Inventor</b>	Jeffers
	<b>Group Art Unit</b>	Not Yet Assigned
	<b>Examiner Name</b>	Not Yet Assigned
	<b>Attorney Docket Number</b>	15966-557A

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
	B1	JP	5301893	Takeda Chem Ind. Ltd. English Abstract	11/16/1993		xxx

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Altschul, et al. (1990). "Basic local alignment search tool." <i>J Mol Biol</i> 215(3): 403-10.
	C2	Basilico and Moscatelli (1992). "The FGF family of growth factors and oncogenes." <i>Adv Cancer Res</i> 59: 115-65.
	C3	Danilenko (1999). "Preclinical and early clinical development of keratinocyte growth factor, an epithelial-specific tissue growth factor." <i>Toxicol Pathol</i> 27(1): 64-71.
	C4	Gasparini (1999). "The rationale and future potential of angiogenesis inhibitors in neoplasia." <i>Drugs</i> 58(1): 17-38.
	C5	GenBank Accession Number: A58788 (06-MAR-1998).
	C6	GenBank Accession Number: AA232729 (27-NOV-1996).
	C7	GenBank Accession Number: AA236522 (27-NOV-1996).
	C8	GenBank Accession Number: AAF00049 (22-JUN-2000).
	C9	GenBank Accession Number: AAF80597 (27-AUG-2001).
	C10	GenBank Accession Number: AB012615 (08-SEP-1999).
	C11	GenBank Accession Number: AB020858 (21-MAY-1999).
	C12	GenBank Accession Number: AF091434 (22-JUN-2000).
	C13	GenBank Accession Number: AI272876 (18-NOV-1998).
	C14	GenBank Accession Number: AI272878 (18-NOV-1998).
	C15	GenBank Accession Number: BAB03265 (26-JUL-2000).
	C16	GenBank Accession Number: E05822 (29-SEP-1997).
	C17	GenBank Accession Number: P36364 (01-NOV-1997).
	C18	GenBank Accession Number: P54130 (16-OCT-2001).
	C19	GenBank Accession Number: P98070 (16-OCT-2001).

OTHER PRIOR ART AND NON-PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C20	GenBank Accession Number: <b>S82023</b> (05-MAY-2002).
	C21	Gerwins, et al. (2000). "Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis." <i>Crit Rev Oncol/Hematol</i> <b>34</b> (3): 185-94.
	C22	Grisham (1994). "Oxidants and free radicals in inflammatory bowel disease." <i>Lancet</i> <b>344</b> (8926): 859-61.
	C23	Klint and Claesson-Welsh (1999) "Signal transduction by fibroblast growth factor receptors" <i>Front. Biosci.</i> <b>4</b> : d165-177.
	C24	Koga, et al. (1999). "Characterization of a novel member of the FGF family, XFGF-20, in <i>Xenopus laevis</i> ." <i>Biochem Biophys Res Commun</i> <b>261</b> (3): 756-65.
	C25	La Rocca, et al. (1990). "Suramin: prototype of a new generation of antitumor compounds." <i>Cancer Cells</i> <b>2</b> (4): 106-15.
	C26	Li, et al. (1997). "Activation of FGF receptors by mutations in the transmembrane domain." <i>Oncogene</i> <b>14</b> (12): 1397-406.
	C27	Lichtiger, et al. (1994). "Cyclosporine in severe ulcerative colitis refractory to steroid therapy." <i>N Engl J Med</i> <b>330</b> (26): 1841-5.
	C28	Lorenzi, et al. (1996). "FRAG1, a gene that potently activates fibroblast growth factor receptor by C-terminal fusion through chromosomal rearrangement." <i>Proc Natl Acad Sci U S A</i> <b>93</b> (17): 8956-61.
	C29	Matsumoto-Yoshitomi, et al. (1997). "Autocrine transformation by fibroblast growth factor 9 (FGF-9) and its possible participation in human oncogenesis." <i>Int J Cancer</i> <b>71</b> (3): 442-50.
	C30	Miyakawa, et al. (1999). "A hydrophobic region locating at the center of fibroblast growth factor-9 is crucial for its secretion." <i>J Biol Chem</i> <b>274</b> (41): 29352-7.
	C31	Miyake, et al. (1998). "Structure and expression of a novel member, FGF-16, on the fibroblast growth factor family." <i>Biochem Biophys Res Commun</i> <b>243</b> (1): 148-52.
	C32	Miyamoto, et al. (1993). "Molecular cloning of a novel cytokine cDNA encoding the ninth member of the fibroblast growth factor family, which has a unique secretion property." <i>Mol Cell Biol</i> <b>13</b> (7): 4251-9.
	C33	Mount (1996). "AT-AC introns: an ATtACK on dogma." <i>Science</i> <b>271</b> (5256): 1690-2.
	C34	Munkholm, et al. (1994). "Frequency of glucocorticoid resistance and dependency in Crohn's disease." <i>Gut</i> <b>35</b> (3): 360-2.
	C35	Nakai and Kanehisa (1992). "A knowledge base for predicting protein localization sites in eukaryotic cells." <i>Genomics</i> <b>14</b> (4): 897-911.
	C36	Naruo, et al. (1993). "Novel secretory heparin-binding factors from human glioma cells (glia-activating factors) involved in glial cell growth. Purification and biological properties." <i>J Biol Chem</i> <b>268</b> (4): 2857-64.
	C37	Pearson, et al. (1995). "Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis." <i>Ann Intern Med</i> <b>123</b> (2): 132-42.
	C38	Present, et al. (1999). "Infliximab for the treatment of fistulas in patients with Crohn's disease." <i>N Engl J Med</i> <b>340</b> (18): 1398-405.
	C39	Revest, et al. (2000). "Fibroblast growth factor 9 secretion is mediated by a non-cleaved amino-terminal signal sequence." <i>J Biol Chem</i> <b>275</b> (11): 8083-90.
	C40	Santos-Ocampo, et al. (1996). "Expression and biological activity of mouse fibroblast growth factor-9." <i>J Biol Chem</i> <b>271</b> (3): 1726-31.
	C41	EMBL Database Accession Number: <b>Q9QY71</b> (1-MAY-2000).
	C42	EMBL Database Accession Number: <b>Q9UL22</b> (1-MAY-2000).
	C43	Szebenyi and Fallon (1999). "Fibroblast growth factors as multifunctional signaling factors." <i>Int Rev Cytol</i> <b>185</b> : 45-106.
	C44	Wozney, et al. (1988). "Novel regulators of bone formation: molecular clones and activities." <i>Science</i> <b>242</b> (4885): 1528-34.

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C45	Xu, et al. (1999). "Fibroblast growth factor receptors (FGFRs) and their roles in limb development." <i>Cell Tissue Res</i> 296(1): 33-43.
	C46	Yates, et al. (1997). "Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance." <i>Ann Intern Med</i> 126(8): 608-14.

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.